
医学资讯CD276化疗耐药
CD276 被确定为晚期胰腺癌化疗耐药的关键驱动因素
By MedXY|2026年5月1日
单细胞分析揭示 CD276/B7-H3 是胰腺导管腺癌化疗耐药的关键调节因子,强调其在促进基底样肿瘤状态和免疫逃逸中的双重作用。
Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.